中生製藥(01177.HK):腫瘤化療止吐藥阿瑞匹坦膠囊獲批上市
格隆匯7月16日丨中生製藥(01177.HK)宣佈,集團開發的腫瘤化療止吐藥“阿瑞匹坦膠囊”(商品名:安多林)(獲批規格:80mg)已獲中華人民共和國國家藥品監督管理局頒發藥品註冊證書,且視同通過仿製藥質量和療效一致性評價。
阿瑞匹坦膠囊作為口服神經激肽-1受體拮抗劑,與其他止吐藥物聯合給藥,適用於預防高度致吐性抗腫瘤化療的初次和重複治療過程中出現的急性和遲發性噁心和嘔吐。阿瑞匹坦可以穿過血腦屏障,高選擇性、高親和性地佔領大腦中的神經激肽-1,從而在中樞層面抑制化療引起的噁心和嘔吐。阿瑞匹坦得到了國內外權威指南的推薦,作為預防高致吐性抗腫瘤化療引起的噁心嘔吐的一線用藥和推薦用藥。
集團再有阿瑞匹坦產品獲批上市,可為國內臨牀醫生和腫瘤患者在抗腫瘤輔助用藥上提供更多的選擇。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.